The FDA didn’t shut down the compounded GLP-1 market with one decision. It dismantled it with two years of them.
Published May 29, 2026 · Epioneum editorial · Regulatory record as of late May 2026 · ~9 minute read
People who follow GLP-1 regulation in headlines tend to remember the big moments. The shortage-list removal. The warning letters. The court fights. The story is shaped that way for ease of telling. The actual record is more granular and more cumulative. Between December 2023 and February 2026, the FDA took at least ten distinct public actions that, together, dismantled the legal terrain compounded GLP-1 telehealth had been built on. This is the chronological record, action by action, with the source for each one.
Adjacent regulators (FTC, state pharmacy boards, presidential memoranda) and private corporate decisions (Novo Nordisk litigation against specific operators) sit outside the scope of this tracker. The point is to show what the FDA itself put on paper, when, and what each piece changed.
December 2023Counterfeit Ozempic enters the legitimate US supply chain and the FDA seizes thousands of units.
On December 21, 2023, the FDA issued an alert warning consumers, pharmacists, and wholesalers not to use counterfeit Ozempic injection 1 milligram in the US drug supply chain. The agency seized thousands of units of the product. The specific product flagged carried lot number NAR0074 and serial number 430834149057.
The seizure is the natural starting point because it established the public regulatory frame for everything that followed. Compounded GLP-1 was already growing in 2023. The counterfeit seizure forced the FDA to begin distinguishing publicly between three categories that consumers were collapsing into one: the brand-name product, legally compounded versions under shortage-list authority, and outright counterfeits in the gray market. The categories matter because each gets a different regulatory tool. The FDA’s December 2023 messaging was the first time it laid out the distinctions explicitly.
July 2024FDA warns of 5-to-20x overdoses with self-administered compounded semaglutide.
On July 26, 2024, the FDA issued a MedWatch alert describing adverse events tied to dosing errors in compounded semaglutide products. The pattern in the reports was specific: patients drawing five to twenty times the prescribed dose from a vial, often because they had no experience with self-injection, were unfamiliar with withdrawing medication from a vial to a syringe, or were confused by measurement units between milligrams, milliliters, and units.
The adverse events the FDA cataloged included nausea, vomiting, abdominal pain, fainting, headache, dehydration, acute pancreatitis, and gallstones. By the end of 2024, the FDA’s Adverse Event Reporting System held more than 900 cases of adverse health events tied to compounded semaglutide or compounded tirzepatide, including 17 deaths. The MedWatch alert was the first FDA action that named the specific consumer-harm mechanism the agency would lean on through 2025 and 2026.
October 2024Tirzepatide comes off the shortage list. The Outsourcing Facilities Association sues that same week.
On October 2, 2024, the FDA removed tirzepatide from its drug shortage list, citing supply data from Eli Lilly demonstrating production and inventory above projected demand. The decision closed the legal door for compounded “essentially copies” of tirzepatide under the shortage-list compounding authority in Section 506(b) of the Food, Drug, and Cosmetic Act.
The door did not close cleanly. On October 7, 2024, the Outsourcing Facilities Association and North American Custom Laboratories sued the FDA in the US District Court for the Northern District of Texas. On October 11, 2024, on the FDA’s own motion, the court remanded the agency’s decision back for reevaluation. The FDA simultaneously announced enforcement discretion windows: 60 days for 503A compounders (running through February 18, 2025), 90 days for 503B outsourcing facilities (through March 19, 2025).
The remand is worth noting structurally. The FDA’s October decision survived the legal challenge in substance, but the schedule of enforcement shifted, and the agency used the months that followed to issue a more formal version of the same decision.
December 2024FDA issues a Declaratory Order confirming the tirzepatide removal.
On December 19, 2024, the FDA issued a Declaratory Order formally confirming the October decision. The order stated the agency had completed its reevaluation and concluded that supply was meeting or exceeding demand for tirzepatide. The Declaratory Order is procedurally significant because it converts an enforcement decision into a more litigation-resistant form. Subsequent court challenges had to engage with the agency’s full record rather than the initial press release.
The court denied subsequent injunctive relief on the tirzepatide challenge, and the enforcement deadlines held. By March 19, 2025, no 503B outsourcing facility could legally compound tirzepatide on the shortage-list authority. By February 18, 2025, neither could a 503A pharmacy under the standard “essentially a copy” framework.
February 2025Semaglutide comes off the shortage list. A second OFA lawsuit follows in three days.
On February 21, 2025, the FDA updated its drug shortage list and resolved the semaglutide shortage that had been in place since 2022. The agency announced enforcement discretion windows mirroring the tirzepatide pattern: 503A compounders had until April 22, 2025; 503B outsourcing facilities had until May 22, 2025.
On February 24, 2025, the Outsourcing Facilities Association filed a second lawsuit, this time challenging the semaglutide decision specifically. The case was docketed as Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.). The plaintiffs requested a preliminary injunction. The structural argument matched the tirzepatide challenge: the FDA’s supply data was insufficient, the decision was arbitrary, and the consequences for patients in active treatment would be severe.
The FDA’s stated position throughout was that the shortage-list mechanism was a temporary supply tool, not a long-term coverage pathway, and that the supply data from Novo Nordisk justified the determination.
April 2025Court denies the OFA’s preliminary injunction. The 503A grace period ends two days earlier.
On April 24, 2025, the US District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a preliminary injunction in the semaglutide case. The court declined to prevent the FDA from enforcing its shortage-resolution decision.
Two days earlier, on April 22, 2025, the 503A enforcement discretion period for semaglutide had already ended. From that date forward, any 503A pharmacy compounding a standard semaglutide formulation as an “essentially a copy” of Wegovy or Ozempic was operating outside the protection the shortage-list authority had provided. State boards of pharmacy and the FDA both had open enforcement pathways.
The 503A pathway did not close entirely. Compounded “personalized” formulations of semaglutide remained available where a prescriber documented a specific clinical justification the FDA-approved product could not meet. The FDA stated, in the February 2025 release and again in subsequent guidance, that templated personalization (boilerplate combinations of semaglutide with B12, pyridoxine, or non-standard dosing applied uniformly across a provider’s patient population) “may not satisfy” the 503A requirement. The agency did not commit to specific case-by-case enforcement at that point, but it put the standard in writing.
May 2025The 503B grace period for semaglutide expires. Mass compounding becomes legally indefensible.
On May 22, 2025, the 503B outsourcing facility enforcement discretion period for semaglutide ended. 503B facilities, which had been the engine of high-volume compounded semaglutide production through 2023 and 2024, lost the legal pathway to continue.
The structural effect on the market was sharp. 503B operators that had built businesses around compounded semaglutide either ceased production, pivoted to other molecules, or attempted to keep producing under increasingly creative legal theories. The FDA’s published position made each of those creative theories progressively harder to defend.
By June 2025, the federal-level legal terrain for mass compounding of standard semaglutide formulations was effectively closed for both pharmacy categories. The market did not vanish. It restructured around the narrower 503A “personalized formulation” lane, with the templated-personalization standard from the February 2025 release sitting as a regulatory hazard above the industry.
September 16, 2025FDA issues 55+ warning letters to online sellers of compounded GLP-1 in a single day.
On September 16, 2025, the FDA issued more than 55 warning letters in a single coordinated action against online sellers of compounded GLP-1 products. The action targeted direct-to-consumer marketing claims, including representations that compounded products were “equivalent” or “comparable” to FDA-approved versions, language about FDA approval applied to products that had received no such approval, and the use of telehealth brand names that obscured the actual compounding source.
One representative letter from this batch, issued to GLP-1 Solution on September 9, 2025, captured the standard pattern. The agency cited misleading direct-to-consumer claims, advised the recipient to respond within 15 business days, and warned of further regulatory action including product seizure and injunction.
The September 2025 action was the largest single-day FDA enforcement event in the compounded GLP-1 space to that point. It signaled a shift from individual pharmacy enforcement toward systematic targeting of the consumer-facing marketing layer.
February 20, 2026FDA names 30 more telehealth companies and threatens product seizure or injunction.
On February 20, 2026, the FDA sent 30 additional warning letters to telehealth companies marketing compounded GLP-1 products. The letters were made public in early March 2026. The pattern of violations cited tracked the September 2025 batch: equivalence claims, sourcing obfuscation through telehealth brand-name labeling, and direct-to-consumer marketing that implied FDA approval.
The escalation in the February 2026 batch was the explicit enforcement language. Each letter included a 15-business-day response window and stated that failure to correct violations could result in product seizure, injunction, or other enforcement action without further notice. The full list of 30 entities is on the FDA’s public warning letter database.
Cumulatively, the two coordinated batches (September 2025 and February 2026) brought the FDA’s total warning-letter count against compounded GLP-1 marketers to more than 85 over six months.
What we still don’t know
Three significant gaps remain.
First, FDA’s enforcement priorities for 2026 are not fully public. The agency has signaled it will continue acting on marketing claims and sourcing transparency, but it has not committed to specific cadence or thresholds for warning-letter conversion into product seizure or injunction. The 15-day response windows from the February 2026 batch run into early-to-mid March. What happens to the non-responsive operators is the next data point worth watching.
Second, the line between legitimately personalized 503A compounding and templated personalization is still being drawn case by case. The FDA’s published position is that boilerplate personalization “may not satisfy” 503A requirements. No appellate ruling has yet defined where exactly the standard sits. State pharmacy boards are interpreting the line differently across jurisdictions.
Third, tirzepatide’s expanding label (sleep apnea approval in late 2024, cardiovascular and renal trials in progress) and any future shortage-list determinations could reopen pathways that the 2024 to 2025 decisions closed. The shortage-list authority is a dynamic regulatory tool, not a one-way door. If supply tightens again on a major molecule, the legal terrain could shift back.
The picture across the full timeline is not a single regulatory shutdown. It is sustained pressure across three layers: shortage-list determinations that closed the broadest legal pathway, court rulings that upheld those determinations, and warning-letter campaigns that targeted the marketing surface where the surviving compounded market reaches consumers.
For a reader trying to evaluate a telehealth provider in 2026, the question is no longer whether the FDA will act. It has acted, repeatedly, for two years. The question is whether the specific operator has restructured its model around the post-shortage rules or is still running the templated-personalization playbook that the agency has now named in writing twice. The provider’s pharmacy disclosure, the standardization of its “personalization” pathway, and the FDA warning-letter database are the three places a careful reader can check. Our own methodology scores pharmacy transparency as one of four axes for exactly this reason.
That answer changes by quarter. The list in this post does not. It is the regulatory record as of late May 2026, and it will keep growing.
This tracker is informational only and is not legal or medical advice. It covers FDA actions specifically; adjacent regulators and private litigation are out of scope. Every entry links to a primary FDA source or, where the court record is on PACER, a legal-industry summary. Spot a factual error or a missing action? corrections@epioneum.com.